10X Genomics Inc (TXG)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $7.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
10X Genomics Inc (TXG) Government Contracts
Federal agencies obligated $6.69M to 10X Genomics over the 12 months through Jul 31, 2026, down 29.1% from the prior 12 months. Department of Health and Human Services was the top awarding agency with 77.2% of obligations across 4 agencies. 10X Genomics had obligation activity on 99 federal contracts over the same 12 months, including 88 new contracts.
Federal Obligations
Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated.
- Obligations
- $6.69M
- Change
- -29.1%
- Obligations to revenue
- 1.0%
| Prior 12 months | $9.43M |
|---|---|
| Contracts with activity | 99 |
| New contracts | 88 |
| Top agency | Department of Health and Human Services |
| Top agency share | 77.2% |
|---|---|
| Agencies | 4 |
| Average remaining term | 7.5 months |
12 months through Jul 31, 2026
Largest New Awards
The 10 largest new awards total $2.63M, and the largest makes up 13.3% of that.
| Award ID | Agency | Amount | Start | End | Description |
|---|---|---|---|---|---|
| 36C24126P0349 | Department of Veterans Affairs, Department of Veterans Affairs | $349,999 | Jun 15, 2026 | Jun 14, 2027 | 10X GENOMICS TEST KITS |
| 36C24225P1431 | Department of Veterans Affairs, Department of Veterans Affairs | $334,143 | Sep 10, 2025 | Sep 9, 2028 | GENE EXPRESSION REAGENTS |
| 75N95D25F40047 | Department of Health and Human Services, National Institutes of Health | $249,991 | Sep 25, 2025 | Oct 24, 2025 | BIOLOGICAL REAGENT MATERIAL - CHROMIUM NEXT GEM SINGLE CELL MULTIOME AND GEM-X SINGLE CELL 5 KITS AND RELATED INDEXES AND CHIPS. |
| 75N93025P01086 | Department of Health and Human Services, National Institutes of Health | $249,964 | Sep 29, 2025 | Sep 28, 2026 | REAGENTS FOR ONGOING NGS PROJECTS (AMBIS 2270566) |
| 75N95D25F40028 | Department of Health and Human Services, National Institutes of Health | $249,934 | Aug 18, 2025 | Nov 17, 2025 | IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - KITS AND REAGENTS USED IN SINGLE-CELL AND GENE PANEL ANALYSES |
| 75N95D25F40044 | Department of Health and Human Services, National Institutes of Health | $249,785 | Sep 24, 2025 | Oct 24, 2025 | IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - GEM-X UNIVERSAL GENE EXPRESSION AND CHROMIUM GEM-X SINGLE CELL CHIPS |
| 75N95D25F40021 | Department of Health and Human Services, National Institutes of Health | $247,506 | Aug 1, 2025 | Oct 31, 2025 | BIOLOGICAL AND REAGENT MATERIAL - GEM-X FLEX GENE EXPRESSION AND SAMPLE PREP/DUAL INDEX KITS |
| 75N95D25F40045 | Department of Health and Human Services, National Institutes of Health | $246,535 | Sep 25, 2025 | Dec 24, 2025 | IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - GEM-X UNIVERSAL GENE EXPRESSION AND GEM-X SINGLE CELL CHIP KITS |
| 75N95D25F40029 | Department of Health and Human Services, National Institutes of Health | $243,284 | Aug 18, 2025 | Nov 17, 2025 | IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - VISIUM HD, HUMAN TRANSCRIPTOME 6.5 MM, 16 RXNS AND DUAL INDEX KIT TS SET A, 96 RXN. |
| 75N95D25F40035 | Department of Health and Human Services, National Institutes of Health | $208,360 | Sep 19, 2025 | Oct 3, 2025 | BIOLOGICAL AND REAGENT MATERIAL - CHROMIUM GEM-X CONSUMABLES. |
Monthly Obligations
The latest complete month, Apr 2026, had $39,953 in obligations. The largest month in the table was Sep 2025, at $3.46M, the last month of the federal fiscal year.
| Month | Obligations |
|---|---|
| Jul 2026 | $116,355 |
| Jun 2026 | $440,899 |
| May 2026 | $60,997 |
| Apr 2026 | $39,953 |
| Mar 2026 | -$0 |
| Feb 2026 | $83,025 |
| Jan 2026 | $55,814 |
| Dec 2025 | $480,172 |
| Nov 2025 | $0 |
| Oct 2025 | $0 |
| Sep 2025 | $3.46M |
| Aug 2025 | $1.95M |
| Month | Obligations |
|---|---|
| Jul 2025 | $1.16M |
| Jun 2025 | $1.05M |
| May 2025 | $635,322 |
| Apr 2025 | $195,394 |
| Mar 2025 | $162,763 |
| Feb 2025 | $859,149 |
| Jan 2025 | $186,295 |
| Dec 2024 | $551,720 |
| Nov 2024 | $128,175 |
| Oct 2024 | $395,589 |
| Sep 2024 | $1.70M |
| Aug 2024 | $2.41M |
Net obligations recorded each month, newest first. Agencies report contract actions with a delay (the Defense Department about 90 days), so the latest months, May to Jul 2026, are still incomplete and the 12-month total usually rises as agencies report the rest.
Frequently Asked Questions About TXG
How much does 10X Genomics receive in federal contracts?
10X Genomics had $6.69M in federal contract obligations over the 12 months through Jul 31, 2026, compared with $9.43M in the 12 months before, down 29.1%. Obligations are contract bookings by the awarding agency, not recognized revenue.
What are 10X Genomics' largest government contracts?
The largest new awards over the 12 months through Jul 31, 2026 were 36C24126P0349, Department of Veterans Affairs, $349,999, started Jun 15, 2026; 36C24225P1431, Department of Veterans Affairs, $334,143, started Sep 10, 2025; 75N95D25F40047, Department of Health and Human Services, $249,991, started Sep 25, 2025.
Which agencies award 10X Genomics contracts?
Department of Health and Human Services was the top awarding agency with 77.2% of obligations over the 12 months through Jul 31, 2026. The records cover 4 agencies. Other agencies in the awards list include Department of Veterans Affairs.
What new federal contracts did 10X Genomics win in the 12 months through Jul 31, 2026?
10X Genomics won 88 new federal contracts in the 12 months through Jul 31, 2026. The largest was 36C24126P0349, Department of Veterans Affairs, $349,999, started Jun 15, 2026.
How do 10X Genomics' federal obligations compare with its revenue?
Federal contract obligations were $6.69M over the 12 months through Jul 31, 2026, equivalent to 1.0% of 10X Genomics' revenue. Obligations are amounts the government committed to contracts in the period, not the share of 10X Genomics' revenue that comes from the government.
TXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts